Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02637934 · ClinicalTrials.gov registry record · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
A Phase 1 study of Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT02637934 is a Phase 1 study of Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02637934, a Phase 1 study of Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Up to 40 evaluable women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer will participate in two different imaging cohorts. The Biodistribution cohort will include up to 4 patients and the Dynamic cohort will include up to 36 patients. Human dosimetry will be calculated from the Biodistribution cohort. The Dynamic cohort date will evaluate preliminary information on uptake of \[18F\]FTT in gynecological cancer and compare with PARP-1 activity in tissue.
Conditions Studied
Interventions
- DRUG [18F]FluorThanatrace
- RADIATION PET/CT imaging sessions
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-01-14 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02637934
The ClinicalTrials.gov registry entry for NCT02637934 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer appearing as the primary indexed condition, and to 2 interventions - of which [18F]FluorThanatrace is the first listed.
NCT02637934 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02637934 about?
NCT02637934 is a clinical study titled "Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT". Up to 40 evaluable women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer will participate in two different imaging cohorts. The Biodistribution cohort will include up to 4 patients and the Dynamic cohort will include up to 36 patients. Human dosimetry will be...
What is the current status of trial NCT02637934?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2016-01-14. Estimated completion is 2026-01.
What conditions does trial NCT02637934 study?
This clinical trial studies the following conditions: Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
What interventions are being tested in trial NCT02637934?
The interventions under investigation include: [18F]FluorThanatrace (DRUG), PET/CT imaging sessions (RADIATION).
Who is sponsoring clinical trial NCT02637934?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02637934 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.